246 related articles for article (PubMed ID: 18804041)
1. Comparison of twin and autologous transplants for multiple myeloma.
Bashey A; Pérez WS; Zhang MJ; Anderson KC; Ballen K; Berenson JR; To LB; Fonseca R; Freytes CO; Gale RP; Gibson J; Giralt SA; Kyle RA; Lazarus HM; Maharaj D; McCarthy PL; Milone GA; Nimer S; Pavlovsky S; Reece DE; Schiller G; Vesole DH; Hari P;
Biol Blood Marrow Transplant; 2008 Oct; 14(10):1118-1124. PubMed ID: 18804041
[TBL] [Abstract][Full Text] [Related]
2. Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation.
Gahrton G; Svensson H; Björkstrand B; Apperley J; Carlson K; Cavo M; Ferrant A; Fouillard L; Gratecos N; Gratwohl A; Guilhot F; Lambertenghi Deliliers G; Ljungman P; Masszi T; Milligan DW; Powles RL; Reiffers J; Samson JD; Stoppa AM; Vernant JP; Volin L; Wallvik J
Bone Marrow Transplant; 1999 Oct; 24(7):741-5. PubMed ID: 10516677
[TBL] [Abstract][Full Text] [Related]
3. Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation.
Kumar S; Pérez WS; Zhang MJ; Ballen K; Bashey A; To LB; Bredeson CN; Cairo MS; Elfenbein GJ; Freytes CO; Gale RP; Gibson J; Kyle RA; Lacy MQ; Lazarus HM; McCarthy PL; Milone GA; Moreb JS; Pavlovsky S; Reece DE; Vesole DH; Wiernik PH; Hari P
Biol Blood Marrow Transplant; 2008 Oct; 14(10):1134-1140. PubMed ID: 18804043
[TBL] [Abstract][Full Text] [Related]
4. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
[TBL] [Abstract][Full Text] [Related]
5. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
[TBL] [Abstract][Full Text] [Related]
6. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
Kyle RA
Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
[TBL] [Abstract][Full Text] [Related]
7. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
[TBL] [Abstract][Full Text] [Related]
8. Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic.
Mir MA; Kapoor P; Kumar S; Pandey S; Dispenzieri A; Lacy MQ; Dingli D; Hogan W; Buadi F; Hayman S; Gandhi M; Gertz MA
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):349-357.e2. PubMed ID: 25958193
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
Reynolds C; Ratanatharathorn V; Adams P; Braun T; Silver S; Ayash L; Carson E; Eisbruch A; Dawson LA; McDonagh K; Ferrara J; Uberti J
Bone Marrow Transplant; 2001 Apr; 27(8):801-7. PubMed ID: 11477436
[TBL] [Abstract][Full Text] [Related]
10. European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma.
Björkstrand B
Semin Hematol; 2001 Jul; 38(3):219-25. PubMed ID: 11486309
[TBL] [Abstract][Full Text] [Related]
11. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.
Qazilbash MH; Saliba R; De Lima M; Hosing C; Couriel D; Aleman A; Roden L; Champlin R; Giralt SA
Cancer; 2006 Mar; 106(5):1084-9. PubMed ID: 16456814
[TBL] [Abstract][Full Text] [Related]
12. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
13. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
Alyea E; Weller E; Schlossman R; Canning C; Mauch P; Ng A; Fisher D; Gribben J; Freeman A; Parikh B; Richardson P; Soiffer R; Ritz J; Anderson KC
Bone Marrow Transplant; 2003 Dec; 32(12):1145-51. PubMed ID: 14647268
[TBL] [Abstract][Full Text] [Related]
14. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
15. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
[TBL] [Abstract][Full Text] [Related]
16. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
Björkstrand B; Iacobelli S; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Musto P; Beksac M; Bosi A; Milone G; Corradini P; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Gahrton G
J Clin Oncol; 2011 Aug; 29(22):3016-22. PubMed ID: 21730266
[TBL] [Abstract][Full Text] [Related]
17. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.
Georges GE; Maris MB; Maloney DG; Sandmaier BM; Sorror ML; Shizuru JA; Lange T; Agura ED; Bruno B; McSweeney PA; Pulsipher MA; Chauncey TR; Mielcarek M; Storer BE; Storb R
Biol Blood Marrow Transplant; 2007 Apr; 13(4):423-32. PubMed ID: 17287157
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
19. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
Gahrton G; Iacobelli S; Bandini G; Björkstrand B; Corradini P; Crawley C; Hegenbart U; Morgan G; Kröger N; Schattenberg A; Schönland SO; Verdonck LF; Volin L; de Witte T; Niederwieser D;
Haematologica; 2007 Nov; 92(11):1513-8. PubMed ID: 18024400
[TBL] [Abstract][Full Text] [Related]
20. A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis.
Gandhi M; Jestice H; Scott M; Bloxham D; Bass G; Craig J; Marcus R
Bone Marrow Transplant; 1999 Aug; 24(4):369-75. PubMed ID: 10467325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]